---
title: "FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286895834.md"
description: "FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News"
datetime: "2026-05-19T02:35:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286895834.md)
  - [en](https://longbridge.com/en/news/286895834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286895834.md)
---

# FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News

### Related Stocks

- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)

## Related News & Research

- [Boston Scientific enters into $2 billion accelerated share repurchase agreement | BSX Stock News](https://longbridge.com/en/news/286758956.md)
- [Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal](https://longbridge.com/en/news/286808399.md)
- [Boston Scientific announces strategic investment in MiRus LLC | BSX Stock News](https://longbridge.com/en/news/286755970.md)
- [Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results](https://longbridge.com/en/news/286942821.md)
- [Securian Asset Management Inc. Sells 31,250 Shares of Boston Scientific Corporation $BSX](https://longbridge.com/en/news/285922673.md)